Intellia Therapeutics Given New 70.00 Price Target at Wells Fargo Company
NTLA Stock | USD 15.21 0.48 3.26% |
About 64% of all Intellia Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that some traders are interested. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
Intellia |
Intellia Therapeutics had its price objective lowered by Wells Fargo Company from 80.00 to 70.00 in a report released on Monday morning,Benzinga reports. Wells Fargo Company currently has an overweight rating on the stock. A number of other equities research analysts have also issued reports on the stock. Robert
Read at thelincolnianonline.com
Intellia Therapeutics Current Investor Sentiment
Panic Vs Confidence
64
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Intellia Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Intellia Therapeutics.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Intellia Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Intellia Therapeutics Historical Investor Sentiment
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.
Intellia Therapeutics Fundamental Analysis
We analyze Intellia Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Intellia Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Intellia Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intellia Therapeutics stock to make a market-neutral strategy. Peer analysis of Intellia Therapeutics could also be used in its relative valuation, which is a method of valuing Intellia Therapeutics by comparing valuation metrics with similar companies.
Peers
Intellia Therapeutics Related Equities
FATE | Fate Therapeutics | 18.28 | ||||
CRBU | Caribou Biosciences | 8.91 | ||||
VERV | Verve Therapeutics | 8.85 | ||||
BEAM | Beam Therapeutics | 5.26 | ||||
SANA | Sana Biotechnology | 4.08 | ||||
DNA | Ginkgo Bioworks | 3.90 | ||||
CRSP | Crispr Therapeutics | 3.10 | ||||
EDIT | Editas Medicine | 0.45 | ||||
VRTX | Vertex Pharmaceuticals | 0.54 | ||||
PRME | Prime Medicine, | 1.20 |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |